We report herein a detailed study concerning the impact of different bioconjugation and nanoformulation strategies on the in vitro targeting ability of peptide-decorated squalenoyl gemcitabine (SQdFdC) nanoparticles (NPs). NPs have been functionalized with the CKAAKN peptide, previously identified as efficient homing device within the pancreatic pathological microenvironment. Two approaches have been followed: (i) either the CKAAKN peptide was directly conjugated at the surface of preformed SQdFdC nanoparticles (conjugation after NP formation) or (ii) it was first reacted with a maleimide squalenoyl derivative before the resulting bioconjugate was co-nanoprecipitated with SQdFdC to form the peptide-decorated NPs (conjugation before NP formation). NPs were characterized with respect to mean diameter, zeta potential and stability over time. Then, their specific interaction with the sFRP-4 protein was evaluated by surface plasmon resonance. Although both the synthetic strategies allowed to formulate NPs able to interact with the corresponding receptor, enhanced target binding and better specific avidity were observed with CKAAKN-NPs functionalized before NP formation.
INTRODUCTION
The ability to selectively deliver drugs to tumor cells with minimal interaction with healthy tissues is a major challenge in chemotherapy. To this aim, suitable ligands able to bind to specific receptors, overexpressed on cancer cells and relatively downregulated on healthy tissues, have been successfully employed as a valuable strategy to specifically target tumors. 1 By means of molecular recognition, such targeted therapy has improved the balance between efficacy and toxicity of conventional systemic anticancer treatments 2 , 3 as observed, for instance, in the case of antibody-conjugated chemotherapeutic agents. [3] [4] [5] Several antibody-drug conjugates are currently included in clinical trials with encouraging results 6 and two examples, Adcetris ® (Takeda, Seattle Genetics) and Kadcyla ® (Roche, Genentech), have recently been approved by FDA and EMA. [7] [8] In parallel, the use of targeting ligands grafted to the surface of nanoscale drug delivery devices (i.e., nanomedicines) appears as another promising approach. 9 Compared to molecular conjugates, nanocarriers offer the advantage to protect the drug molecule from degradation and to better control drug release. Moreover, by tuning the number of ligand molecules onto the nanocarrier surface, targeting efficacy might be improved via a multivalent binding process. 10 ligand, (ii) the selected coupling reaction, (iii) the disposition of the ligand at the surface and (iv) the ligand surface density. [17] [18] [19] [20] [21] [22] Two main ligation strategies have been used to display the targeting agents at the surface of the nanocarriers: the ligand can either (i) be directly coupled in aqueous solution to the surface of preformed nanocarriers or (ii) be linked to the nanocarrier components prior to nanocarrier construction ( Figure 1a ).
The first strategy is generally preferred because the ligand is directly grafted onto the nanoparticle surface and available for the receptor recognition, whereas the linkage of bulky ligands (such as polypeptides, proteins or antibodies) to the nanocarrier building material might alter its hydrophilic/lipophilic balance and its self-assembly properties. 11 An undeniable advantage of the second strategy relies on the possibility to control the reaction yield, to purify and characterize the resulting conjugate. However, the solubilization in organic solvents, that is sometimes required, could cause denaturation of the proteins or antibodies compromising their affinity for the receptor. In addition, in this approach the ligand is susceptible of entrapment into the nanocarrier core during nanoparticle preparation, leading to insufficient surface coverage and lower availability for interaction with the corresponding receptor.
Therefore, a comparative study about advantages/disadvantages of each strategy should be done for any new system, in order to achieve successful actively targeted nanoparticles. In this study, we report a rational approach for the design of ligand-targeted squalene-based nanoparticles for specific drug delivery to pancreatic tumor cells. The "squalenoylation" approach consists in the chemical linkage of squalene (SQ), a natural triterpene precursor in the sterol biosynthesis, to biologically active molecules. The obtained lipid bioconjugates are able to self-assemble in aqueous solution to form stable nanoparticles with high drug payloads. 23 Such innovative concept has firs been applied to gemcitabine (dFdC), which is the first-line therapeutic agent in pancreatic cancer treatment. 24 After intravenous administration, 4-(N)-trisnorsqualenoylgemcitabine (SQdFdC) nanoparticles exhibited impressively greater anticancer activity than the free drug against different tumor models (e.g., experimental leukemia and pancreatic cancer). 23, [25] [26] [27] However, the physio-pathological complexity of pancreatic cancer 28 urgently required the development of better targeted therapeutic approaches to enhance selective nanoparticle internalization by cancer cells, also avoiding potential side effects.
In this context, functionalized SQdFdC nanoparticles were prepared by linking the CKAAKN peptide, previously identified as efficient homing device within the pancreatic pathological microenvironment by phage display screening. 29 These nanoparticles were found to be more efficient than non CKAAKN-functionalized nanoparticles on a transgenic mice model of pancreatic cancer. 30 Herein, we performed a comparative study to establish the optimal CKAAKN peptide-SQdFdC nanoparticle ligation strategy. Briefly, CKAAKN peptide was 
RESULTS AND DISCUSSION
Preparation and characterization of non targeted nanoparticles. In order to obtain stable CKAAKN-functionalized SQdFdC nanoparticles, the formulation of the colloidal system was deeply investigated by tuning the preparation conditions. In particular, a maleimide groupbearing squalene derivative (SQMal) able to link the peptide via its thiol function was added to SQdFdC (1) in various molar ratios. Moreover, two different spacers were introduced between the squalene moiety and the maleimide group. In the case of the SQMallipo (3), 30 a 6-carbon atom lipophilic chain served as a spacer, while for the SQMalhydro (4), 31 All NPs were prepared by nanoprecipitation, using acetone or ethanol as organic solvent and without adding any surfactant. Maleimide-bearing SQdFdC NPs were prepared by adding SQMallipo or SQMalhydro.
SQdFdC and SQMallipo were co-nanoprecipitated at various SQdFdC/SQMallipo molar ratios (10:1, 5:1, 2:1) with a constant SQdFdC concentration (either in acetone or in ethanol), giving a suspension of narrow monodispersed NPs (N1). Addition of SQMallipo led to a slight size increase compared to SQdFdC NPs which displayed a mean diameter of 141 nm and 122 nm when prepared in acetone (N0a) or ethanol (N0e), respectively (Table 1) .
SQdFdC/SQMalhydro NPs (N2) were prepared by co-nanoprecipitation of SQdFdC and SQMalhydro at two molar ratios (10:1, 5:1), with a constant SQdFdC concentration. Ethanol turned out to be the best solvent, while when acetone was employed NPs instantly aggregated.
As observed for SQdFdC/SQMallipo, N2e displayed a mean diameter of less than 200 nm and a narrow particle size distribution (Table 1) . However, the presence of an ether chain between the maleimide group and the squalene moiety affected the nanoparticle stability, probably due to a modification of the internal inverted hexagonal phase structure of SQdFdC nanoparticles.
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On the contrary, a higher stability was observed when a lipophilic chain was used as spacer (SQMallipo).
According to these results, the SQMallipo was preferred to the SQMalhydro for the preparation of peptide-targeted SQdFdC nanoparticles. Acetone was selected as solvent due to the higher colloidal stability of N1a nanoparticles compared to those prepared in ethanol (N1e). Using acetone as solvent and a low or medium amount of SQMallipo (SQdFdC/SQMallipo 10:1 or 5:1), no precipitation was detected after 1-week storage at 4°C. [35] [36] [37] [38] ; they also supported the choice of using only the acetone-formulated SQdFdC/SQMallipo NPs for further investigations.
Preparation and characterization of targeted nanoparticles by coupling CKAAKN peptide to preformed nanoparticles. As mentioned before, the CKAAKN peptide is able to react with the maleimide function of the spacer via the cysteine thiol group present in its sequence, leading to the formation of a stable thioether bond. Noteworthy is that this site of derivatization does not alter the ligand/receptor recognition, as confirmed by the fact that the same function was used for performing the previous phage display in vivo screening. 29 CKAAKN conjugation on preformed nanoparticles allows peptide moieties to be disposed only at the surface of the carriers, thus being more available for the receptor recognition. For this purpose, the peptide thiol group was reacted with maleimide functions of N1a (SQdFdC/SQMallipo molar ratio 10:1 or 5:1) using different Mal/peptide molar ratios (1:0.5 or 1:0.25) to obtain N1a-P. Targeted NPs showed a higher mean diameter compared to untargeted ones ( Table 1) . In some cases, aggregation occurred and/or the stability was very low. The zeta potential value increased with the peptide amount (from -23 to -10 mV), probably due to the presence of two protonable amino groups in the CKAAKN moiety ((2) Figure 2 ).
SQdFdC/SQMallipo/CKAAKN molar ratio 5:1:0.25 NPs (N1a-P*) showed the highest stability and only this nanoformulation was therefore used for further studies. The analyses of the amount of conjugated peptide on these NPs revealed the presence of 106866 peptide molecules
The interaction between the thiol groups and maleimide functions onto N1a surface was investigated by isothermal titration calorimetry (ITC) analysis. This technique is widely used in nanotechnology for characterizing thermodynamics and stoichiometry of intermolecular interactions allowing the evaluation of the association constant (K), the stoichiometry, the enthalpy (ΔH) and the entropy (ΔS) from which the Gibbs free energy (ΔG) of the process can be calculated. [39] [40] [41] The heat flows were determined when peptide aliquots were added to N0a To be noted that, according to ITC results, the Michael addition reaction occurred in a larger extent for CKAAKN/Mal molar ratios (N) higher than 0.5. On the light of these results, it appeared that the CKAAKN/Mal molar ratio (1:0.25) used to formulate the N1a-P* led to the co-existence of both non-covalent interactions (demonstrated by ITC in other cases such as bio-molecular recognition or inclusion complexes [39] [40] [41] ) and covalent conjugation of the CKAAKN onto the NP surface (Figure 1b -vi) . However, higher CKAAKN/Mal molar ratios could not be used because they led to N1a aggregation, (Table 1) SQdFdC/SQCKAAKN 1:0.01 molar ratio NPs (N4-P*), which showed a significant decrease of the absolute surface charge compared to untargeted NPs (N0e) (-6 vs -22 mV) and only a slight increase of the mean diameter, were chosen for further investigations. According to the hydrophilic nature of the peptide we might assume that during the nanoprecipitation process the CKAAKN molecules localize on the NP surface. On the basis of the SQdFdC/SQCKAAKN 1:0.01 molar ratio used for N4-P* formulation, a value of 28385 molecules of CKAAKN per NP was obtained. Interestingly, N4-P* showed a marked reduction of the zeta potential value when increasing the pH of the medium from 7.4 to 9.8 ( Figure 4 ). This probably resulted from the deprotonation of the lysine amino groups, thus supporting again the hypothesis of the presence of the peptide onto the surface of the nanoparticles, which is a crucial parameter to obtain an efficient targeting towards cancer cells. Only a slight increase of N4-P* mean diameter has been observed over a period of 72 h after incubation at 37 °C in water and in cell culture medium containing 10% FBS (SI Figure S4) . Surface plasmon resonance analysis. While for N4-P* the peptide was covalently conjugated to the nanoparticle surface, in the case of N1a-P* the ITC results suggested both adsorption and conjugation of the peptide on the NP surface. Covalent conjugation, in contrast to adsorption, ensures a stronger association between the ligand and the nanoparticles, especially after in vivo administration. 44 However, ligand association to the nanoparticle by weak interactions or surface adsorption has also been proven as an alternative strategy to tailor targeted nanoparticles. [44] [45] Therefore, both coupling strategies were further investigated and the peptide targeting capability of N1a-P* and N4-P* was evaluated by surface plasmon resonance (SPR). Since it was reported that the sequence CKA-K shared motifs with the Wnt-2 protein 29 , sFRP-4, a secreted frizzled-related protein that binds Wnt-2, was immobilized onto the sensor chip surface. 30, 46 The ability of the free CKAAKN peptide to specifically interact with the sensor chip-immobilized sFRP-4 was also verified. 30 Although both N1a-P* and N4-P* were able to specifically interact with the receptor (which was not the case for untargeted N0e), N4-P* enabled to reach the more important plasmonic signal after PBS washing ( Figure 5 ). The enhanced target binding and specific avidity of N4-P* suggested that the peptide conjugation prior to nanocarrier formation was the most efficient methodology to obtain enhanced binding and avidity, ensuring stronger association between nanoparticles and sFRP-In vitro studies. In order to confirm the on the bench SPR results, the receptor targeting ability as a function of the synthetic strategy was evaluated in in vitro cell culture experiments.
To this purpose, a preliminary Western Blot analysis on several cell lines was performed in order to assess their frizzled-5(FZD-5) receptor expression (SI Figure S2) . The MIA PaCa-2 cells were identified as high FZD-5-expressing cells and this result was further confirmed by immunocytochemistry (SI Figure S3) . MIA PaCa-2 cells were then incubated for 6 h with BChol-green-labeled N0e, BChol-green-labeled N1a-P* or BChol-green-labeled N4-P*. Values represent mean ± SEM. Statistical difference N0e vs N4-P* and N1a-P* vs N4-P* (Student's t-test with Bonferroni correction for multiple comparisons) is marked by ** (p < 0.01).
Although slight differences were detected after treatment with N0e and N1a-P*, remarkably the cell fluorescence intensity dramatically increased (by 14-fold) after N4-P* incubation ( Figure   6a ). These results clearly indicated a more efficient internalization of N4-P* in comparison to N1a-P* in MIA PaCa-2 cells.
When cells were incubated at 4 °C, the internalization of N4-P* dramatically decreased, suggesting that peptide-functionalized NPs were internalized via an energy dependent route.
The internalization of the nanocarrier is a key issue for the drug to be efficient. 52 Thus, in order to investigate whether the peptide functionalization enabled to achieve an increased drug efficacy compared to the untargeted NPs, the in vitro cytotoxicity of the different NPs and the free drug was investigated. As previously reported 25 , all NPs were less cytotoxic than free dFdC due to their prodrug nature. Nevertheless, N4-P* caused a higher cytotoxicity compared to both N0e and N1a-P* (Figure 6b ). It is worth mentioning that for N4-P* the 50% inhibition of cell viability (IC50) was already reached at 30 nM (eq. dFdC), while untargeted N0e were not efficient in killing cancer cells in these conditions. These results clearly demonstrated the ability of CKAAKN-functionalized NPs not only to keep the anticancer activity of the SQdFdC, but also to significantly enhance the cytotoxicity. As expected, according to the ITC, SPR and internalization data, N1a-P* did not improve cytotoxicity in comparison to N0e treatment, thus suggesting the absence of specific tumor targeting ability when the peptide was mainly adsorbed at the NP surface.
To further investigate the ability of N4-P* to specifically target cancer cells, the interaction with NIH/3T3, a non cancerous fibroblastic cell line, was studied and compared to the uptake by MIA PaCa-2 cancer cells. Western blot analysis showed that NIH/3T3 healthy cells displayed a low expression of FZD-5 receptor (Supporting Information S2). As shown in Figure   7 , non-functionalized nanoparticles (N0e) were taken-up mainly by NIH/3T3 fibroblasts in a nonspecific manner, resulting in higher accumulation in this cell line. On the contrary, N4-P* were internalized into MIA PaCa-2 cells by a receptor-mediated mechanism, which allowed nanoparticles achieving highly selective tumor cell uptake and toxicity, while decreasing nonspecific accumulation into healthy cells ( Figure 7a Fluorescently-labeled nanoparticles were prepared as described above. The stability of N4-P* has been investigated over a period of 72 h after incubation at 37 °C in water and in cell culture medium containing 10% FBS.
Surface plasmon resonance (SPR) analysis.
Interaction analyses were performed on a BIAcore T100 instrument using CM5 Series S sensor chip from GE Healthcare Life Sciences 
